Ovarian hyperstimulation syndrome (OHSS) is a potential complication of ovarian stimulation in the treatment of infertility. Severe forms of OHSS appear in 0.5-5.0% of in vitro fertilization (IVF) cycles. 1 A critical condition develops with massive ascites or pleural effusion, dyspnea, hemoconcentration and oliguria that can be life-threatening. The underlying cause is an increase in the capillary permeability of the ovaries and mesothelial surfaces with extravasation of protein-rich fluid, which in turn causes hypovolemia, reduced organ perfusion and the risk of thromboembolism. Several angiogenic and vasoactive cytokines, including vascular endothelial growth factor (VEGF), interleukin (IL)-6, IL-8, tumor necrosis factor-α (TNF-α) and angiotensin II, produced from multiple corpora lutea were attributed to pathogenetic factors.
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A better understanding of the underlying pathophysiologic and signal mechanisms would be helpful for prevention and treatment.
Human Chorionic Gonadotropin is a Contributing Inducing Factor of OHSS 
Ovarian Hyperstimulation Syndrome (OHSS): New Strategies of Prevention and Treatment
IL-6, TNF-α and angiotensin II that contribute to OHSS are unclear and need further clarification.
Prevention of OHSS
Coasting with cessation of gonadotropin has been widely adopted to reduce OHSS in high-risk conditions with massive follicular growth. 4 Use of LH for the Replacement of hCG in Triggering Oocyte Maturation
The development of recombinant LH (rLH) may offer an opportunity to replace hCG. The European rLH study group performed a prospective and comparative study on the effective dose of rLH required to induce oocyte maturation and luteinization in patients undergoing IVF. 5 A dose of 15,000-30,000
IU rLH compared with 5000 IU hCG resulted in a similar number of oocytes, embryos and pregnancies. The use of rLH achieved a significant reduction in OHSS compared with hCG. More effort should be made to use rLH as an alternative to hCG as the standard method for induction of oocyte maturation and OHSS prevention.
Use of GnRH Agonist to Induce LH Surge in Non-agonist or Antagonist Cycles
GnRH agonist can stimulate the release of LH and follicle stimulating hormone. It has been used to induce endogenous LH surge in ovulation induction. However, the pregnancy rate was lower than that with the use of hCG. This disappointing result has been attributed to a luteolytic effect caused by the agonist. The introduction of GnRH antagonist protocols has resulted in renewed interest in the use of GnRH agonist to trigger ovulation. Recently, a prospective randomized controlled study of IVF patients found no differences in the number of mature oocytes, fertilization rates, embryo development and implantation rates between the GnRH agonist and hCG groups. 7 The risk of OHSS was significantly reduced in the former group. The use of GnRH agonist to induce final oocyte maturation in the antagonist protocol with appropriate luteal support may be a good alternative to avoid OHSS and deserves further investigation.
Dopamine Agonist (Cabergoline) Inhibits VEGFR-2-mediated Vascular Hyperpermeability
The downstream signals of VEGFR-2 in endothelial cells for vascular permeability in OHSS may involve VE-cadherin 8 and merits further delineation.
It was recently found that dopamine or dopamine receptor 2 (DR-2) agonists transact inhibition of VEGFR-2 dependent vascular permeability and angiogenesis through DR-2 of endothelial cells. 9 Gomez et al first investigated the effect of DR-2 agonist (cabergoline) on OHSS in a rat model. 10 They found that a low dose of cabergoline reversed vascular permeability without affecting luteal angiogenesis. Alvarez et al conducted a pilot study on patients at risk of developing OHSS who were given cabergoline (0.5 mg/day) orally from the day of hCG for 9 days. 1 They observed that ascites, hemoconcentration, vascular hyperpermeability and OHSS were significantly reduced. They further demonstrated that implantation and pregnancy outcome were not affected by cabergoline treatment. 11 However, the case number in their series was small. In addition, angiogenesis is a fundamental step in implantation and pregnancy.
The effects of cabergoline on OHSS, angiogenesis of implantation and pregnancy outcome deserve further study.
Conclusions
Fluid, electrolyte and albumin supplements or paracentesis and thoracentesis have been used as primary treatments for severe OHSS. may deserve further investigation. The use of rLH for inducing oocyte maturation is imperative in the prevention of OHSS in the future. The mechanisms and management of OHSS are summarized in the Figure. 
